Free Newsletter
VLP tech recognized as top-10 medical innovation
The Cleveland Clinic has recognized Novavax's use of genetically engineered virus-like particles in new vaccines as one of the year's top 10 medical innovations at its annual innovation summit.
Novavax develops recombinant structures that essentially look like a virus but don't have the genetic material needed to make them dangerous. Because they look like virus particles to the immune system, the body mounts a potent response that can stop the actual virus in its tracks. And the company says its technology is far less expensive and will be far more efficient in production.
"VLPs represent a very promising approach to preventing the spread of influenza as we recently demonstrated with the announcement of favorable results in a Phase IIa human clinical trial of our VLP based pandemic influenza vaccine," said CEO Dr. Rahul Singhvi.
- read the report from Medical News Today
Related Articles:
Novavax bird flu vaccine shows promise in trial
Flu deaths trigger rise of biotech stocks (May 2006)
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
